Medical Pharmacology: Cancer Chemotherapy Drug Practice Questions

Clearance of platinum analogues e.g. cisplatin:
1. Renal; urinary excretion
2. Dosage adjustment needed for patients with renal insufficiency
3. Both
4. Neither
Carboplatin:
1. Primary dose-limiting toxic effect is myelosuppression.
2. Frequently used in transplant protocols to manage hematologic cancers refractory to other approaches
3. Both
4. Neither
Tumor cells that develop resistance to carboplatin or cisplatin are likely to be cross resistant to oxaliplatin.
1. True
2. False
Initial FDA-approved use of oxaliplatin was as a second-line therapy for metastatic colorectal cancer. Oxaliplatin in this setting was combined with 5-fluorouracil in the FOLFOX treatment regimen.
1. True
2. False
Neurotoxicity, anadverse effect, dose-limiting in nature, is associated with this platinum analog anticancer agent.
1. Carboplatin
2. Cisplatin
3. Oxaliplatin
4. All of the above
Resistance to platinum analog anticancer drugs:
1. Carboplatin and cisplatin exhibit cross-resistance
2. Platinum-DNA adduct repair requires the nucleotide excision repair (NER) pathway
3. Both
4. Neither
Resistance to this platinum analog anticancer drug appears to require DNA mismatch repair proteins (MMR proteins; hMLH1, hMLH2 or hMSH6):
1. Cisplatin
2. Oxaliplatin
3. Both
4. Neither
Loss (or inhibition) of the nucleotide excision repair pathway increases cisplatin sensitivity in ovarian cancer.
1. True
2. False
Basal-type breast cancer (BRCA1 + BRCA2 mutations) appears uniquely sensitive to cisplatin due to upregulation of apototic pathways.
1. True
2. False
Cisplatin when combined with bleomycin, ifosfamide, etoposide, or vinblastine is curative in about 90% of individuals with testicular cancer.
1. True
2. False